Rapid diagnosis of ataxia-telangiectasia by flow cytometric monitoring of DNA damage-dependent ATM phosphorylation

Leukemia

Volumn 23, Issue 2, 2009, Pages 409-414

  Honda, M ^a   Takagi, M ^a   Chessa, L ^b   Morio, T ^a   Mizuatni, S ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; DNA; SERINE;

ATAXIA TELANGIECTASIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA DAMAGE; FLOW CYTOMETRY; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; HUMAN CELL; LETTER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 60149094025     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.195     Document Type: Letter

References (8)

1. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995; 4: 2025-2032.
2. Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull 2007; 81-82: 129-147.
3. Stankovic T, Stewart GS, Byrd P, Fegan C, Moss PA, Taylor AM. ATM mutations in sporadic lymphoid tumours. Leuk Lymphoma 2002; 43 1563-1571.
4. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-168.
5. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421 499-506.
6. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K, Kakizoe T. A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 1993; 47: 73-78.
7. Horibe S, Takagi M, Unno J, Nagasawa M, Morio T, Arai A et al. DNA damage check points prevent leukemic transformation in myelodysplastic syndrome. Leukemia 2007; 21: 2195-2198.
8. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25: 5448-5457.